Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul-Aug;51(4):191-5.
doi: 10.1016/j.regg.2015.11.006. Epub 2016 Jan 13.

[Risk/benefit assessment in the treatment of Alzheimer's disease. Drug interactions]

[Article in Spanish]
Affiliations

[Risk/benefit assessment in the treatment of Alzheimer's disease. Drug interactions]

[Article in Spanish]
María Jesús Hernández-Arroyo et al. Rev Esp Geriatr Gerontol. 2016 Jul-Aug.

Abstract

Introduction: Anticholinergic drugs reduce the efficacy of acetylcholinesterase inhibitors (AChEI) and are inappropriate in elderly patients. The aim of this study is to determine the prevalence rate of prescription AChEI drugs and anticholinergics in a Healthcare Area, to identify the affected patients, and to inform the attending physicians, in order to evaluate the suitability of treatments.

Material and methods: A descriptive cross-sectional observational study of prevalence. Patients on treatment with AChEI and any anticholinergic drug in the first quarter of 2015 were selected. The review of Duran et al. was used as reference to identify anticholinergics, assigning a score to each drug according to its anticholinergic potency. Physicians were provided with a report about the interaction, the list of affected patients, and recommendations.

Results: A total of 486 patients were included in the study, representing 59.0% of total patients with Alzheimer's disease in the Area. There were 66.0% women, and 86.8% of the patients were older than 75 years, and with a mean of 9.2 drugs per patient. The mean number of anticholinergic drugs was 1.6, and 38.3% of patients were prescribed various anticholinergic drugs, with 23.9% on high potency anticholinergic drugs. A statistically significant association was found between taking an anticholinergic and AChEI concomitantly (P=.000; OR: 3.9).

Conclusions: The prevalence of interactions between AChEI and anticholinergic drugs is relevant, considering that it affects vulnerable members of the population. Providing physicians with information about the interaction could help them make clinical decisions, and could improve patient safety, as well as health outcomes.

Keywords: Acetylcholinesterase inhibitors; Anticholinergics; Anticolinérgicos; Drug interactions; Inhibidores de la acetilcolinesterasa; Interacciones farmacológicas; Intervención farmacéutica; Patient safety; Pharmaceutical intervention; Seguridad en el paciente.

PubMed Disclaimer

Similar articles

Substances